Aims This study aims to assess prognostic impact of Framingham criteria for heart failure (FC-HF) in patients with stable heart failure (HF) with preserved ejection fraction (HFpEF).
Introduction
Heart failure (HF) is commonly categorized by left ventricular ejection fraction (LVEF) into HF with reduced ejection fraction (LVEF <40%), HF with midrange ejection fraction (LVEF 40-49%), or HF with preserved ejection fraction (HFpEF; LVEF HF and is based solely on symptoms and clinical findings. Thereafter, the importance of natriuretic peptides (NPs) and refined echocardiographic measurements for the diagnosis of HF were recognized, as reflected in the European Society of Cardiology (ESC) HF guidelines 2016 1 and in the design of more recent HF trials including HFpEF studies such as the PARAGON trial.
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The HFpEF syndrome is associated with non-cardiovascular (CV) co-morbidities that may cause symptoms resembling those of HF, for example, chronic obstructive pulmonary disorder, which may complicate diagnosis. 7 Therefore, there is increasing recognition of the need for suitable definitions of HFpEF and inclusion/exclusion criteria in HFpEF trials.
After an acute HF event, patients are often assigned a diagnosis of chronic HF. However, to what extent signs and symptoms persist chronically, whether definitions of HFpEF continue to be met, and the prognostic role of signs, symptom, and HFpEF criteria, over time, are unknown. Therefore, the aim was to assess the prognostic impact of FC-HF and different descriptive models of HFpEF, based on echocardiography, NPs, and FC-HF, in stable HFpEF patients after an acute HF event.
Methods
This analysis was based on the Karolinska-Rennes (KaRen) study, a European multicentre prospective observational study designed to characterize HFpEF and to identify prognostic factors for long-term mortality and morbidity. 8 Patients presenting to hospital with acute HF were screened and included provided that they fulfilled signs and symptoms of HF according to FC, 5 and LVEF ≥45% at echocardiography within 48 h, and N-terminal pro brain natriuretic peptide (NT-proBNP) >300 ng/L or BNP >100 ng/L. The LVEF cutoff reflected the definition of HFpEF at the time of study design. 8 Out of the 539 patients enrolled, 438 returned for the stable state revisit after 4-8 weeks, 13 (2.4%) patients died before the planned follow-up, and 88 patients (16%) declined or were unable to return. The patients in this analysis had to have FC reassessed at the 4-8 week follow-up. This visit was defined as baseline for assessing subsequent outcomes in the present analysis. At this visit, in addition to clinical assessment including the FC, patients underwent detailed echocardiography, medical history, and blood sampling including NPs. The echocardiographic assessment was performed on a ViVid 7 echo-platform (GE VingMed, Horten, Norway) and analysed in a dedicated core centre in Hôpital Pontchaillou, Rennes, France. Each examination was interpreted once, and measurements were performed three times and averaged by an echocardiographer blinded to the specific clinical history of the patient.
Estimated glomerular filtration rate was calculated according to the Modification of Diet in Renal Disease equation, and NPs were analysed in the local hospital laboratory. Quality of life was assessed with the Minnesota Living with Heart Failure Questionnaire.
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Framingham criteria for heart failure
The FC-HF consists of major (paroxysmal nocturnal dyspnoea, orthopnea, jugular venous distension, third heart sound, cardiothoracic ratio >0.5 on X-ray, pulmonary oedema on X-ray, and pulmonary crackling rales) and minor [peripheral oedema, nocturnal cough, dyspnoea at exercise, hepatomegaly, pleural effusion, and tachycardia (defined as ≥100 bpm)] criteria. To fulfil the FC-HF, the presence of two major or one major + two minor criteria is required.
5
Descriptive models of heart failure with preserved ejection fraction
The four descriptive models of HFpEF were used for which the FC-HF was required for all ( Figure 1 ). In addition, in descriptive models 2-4, HFpEF criteria from the ESC guidelines and the PARAGON trial 6 were added. The descriptive models were (i) FC-HF only; (ii) FC-HF + NPs in sinus rhythm >300/100 and in atrial fibrillation >900/400 ng/L for NTproBNP or BNP, respectively; (iii) FC-HF + NPs + ESC echocar- (Figure 1 ).
Primary endpoint
Patients were followed by telephone call every 6 months up to 18 months regarding potential hospitalizations and mortality until study closure in November 2012. This information was used for the primary composite endpoint of all-cause mortality and HF hospitalization analysed according to our HFpEF descriptive models. All events were adjudicated by and defined according to clinical judgment by the local investigator. The study involved no intervention, and patients were managed routinely by their own physician.
Statistics
Descriptive data were presented as median [interquartile range (IQR)] or number (%) and compared with the Wilcoxon rank sum test and Pearson χ 2 test (Table 1) . Kaplan-Meier analysis was used to assess the study composite endpoint consisting of survival time free from HF hospitalization. The association between the individual FC as well as HF according to the four descriptive models of HFpEF and the composite endpoint was assessed in univariable and multivariable Cox regression models. In addition to the composite endpoint, CV death and non-CV death were analysed as independent variables censoring for death of unknown cause. In the adjusted model, sex, age, glomerular filtration rate, haemoglobin, sodium, body mass index, systolic blood pressure, atrial fibrillation/flutter, coronary artery disease, chronic obstructive pulmonary disease, type 2 diabetes mellitus, and New York Heart Association (NYHA) class were included, all with known impact on morbidity and mortality.
Due to non-normal distribution, plasma and serum NPs were analysed in log-transformed format. P-values were two-sided, and statistical significance was set at 0.05. Statistical analyses were performed using STATA software version 13.1.
Ethics
The French Ethics committees and the ethical review board at Karolinska Institutet approved the KaRen study, which was conducted according to International Conference on Harmonization and Good Clinical Practice guidelines and the Declaration of Helsinki. Written informed consent was obtained from all patients.
Results
Patients
A total of 539 patients with acute HFpEF were enrolled in the KaRen study ( Figure 1 , Table 1) . 10 Of these, 13 (2.4%) died during the hospitalization or after hospitalization but before 
Presence of individual Framingham criteria according to heart failure with preserved ejection fraction descriptive models
The distribution of each individual FC according to our descriptive models is given in Figure 2 . Dyspnoea on exertion was the most prevalent criteria followed by peripheral oedema. In 292 patients, FC-HF (at least two major or one major and two minor criteria) was not fulfilled at the baseline visit, but single FC could still have been present. The most commonly occurring single FC in descriptive model 0 was dyspnoea at exercise (63%) and peripheral oedema (22%). Among the FC, in particular, nocturnal cough, rales, and congestion on X-ray were absent in this group.
Follow-up time and primary endpoint of freedom from all-cause mortality and heart failure hospitalizations
The median follow-up time was 19 months (IQR 9-34 months), and the composite endpoint occurred in 186 Failure Questionnaire; NT-proBNP, N-terminal pro brain natriuretic peptide; NYHA, New York Heart Association; p-glu, plasma glucose; QoL, quality of life; renal disease, self-reported, chart reported, or creatinine ≥100 mmol/L; SBP, systolic blood pressure; T2DM, type 2 diabetes mellitus.
Data presented as median (interquartile range) or n (%).
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(47%) of the patients out of which 93 patients died (23%) (Figures 3-4) . CV mortality constituted 38% (35 patients) and non-CV 37% (34 patients). The cause of death was unknown in 24 patients (26%). The survival free from HF hospitalization by Kaplan-Meier analysis is shown in Figure 3 . Not surprisingly, patients without FC (descriptive model 0) had the best prognosis. For the rest, the probability for fulfilling the primary endpoint significantly increased as NPs, and especially, echocardiography criteria were added. After covariate adjustment, no descriptive model independently predicted the primary composite endpoint (Figure 4) , but there was a trend towards significance when adding NPs and echocardiographic criteria to FC-HF with the strongest trend seen when adding the PARAGON criteria (descriptive model 4). Among the single FC, only pleural effusion predicted the composite endpoint in adjusted model, hazard ratio (HR) 3.38 [95% confidence interval (CI)] ( Table 2 ) with prevalence 7-10% in descriptive models 1-4 ( Figure 2) . In addition to the primary endpoint, associations between the different HF descriptive model and CV death and non-CV Adjustments for gender, age, glomerular filtration rate, log haemoglobin, log sodium, systolic blood pressure, atrial fibrillation, coronary artery disease, chronic obstructive pulmonary disease, type 2 diabetes mellitus, cancer, and New York Heart Association class.
Figure 2
Prevalence of individual Framingham criteria for heart failure at stable state according to the four descriptive models of heart failure with preserved ejection fraction clarified in the methods section.
Prognostic impact of Framingham heart failure criteria in HFpEF death were explored. In unadjusted analyses, both CV death and non-CV death were significantly associated with all four descriptive models of HFpEF. In adjusted multivariable analyses, none of the descriptive models were significantly associated with CV death, but interestingly, descriptive models 2 and 4 were predictors of non-CV death, HR 2.75 (95% CI 1.02-7.42, P-value 0.045) and HR 2.97 (95% CI 1.04-8.47, P-value 0.041), respectively.
Discussion
This is to our knowledge the first study to assess the prognostic importance of FC-HF in ambulatory HFpEF patients following an acute HF hospitalization. Prevalence of HFpEF according to the FC-HF was present in a quarter of patients, whereof 10% were in NYHA class IV. Most met NP and echocardiography criteria for HF. Residual FC-HF at follow-up tended to be associated with increased risk for mortality and HF hospitalization, further strengthened by NPs and echocardiographic criteria, highlighting its role in clinical risk assessment.
Heart failure with preserved ejection fraction characteristics
As expected in HFpEF patients, 11,12 the patients in KaRen were old [mean age 79 years for patients fulfilling FC-HF (descriptive model 1)], were often female, and had a high prevalence of atrial fibrillation. Moreover, our HFpEF patients Figure 4 Heart failure with preserved ejection fraction according to the four descriptive models, clarified in the section, as predictors of all-cause mortality/heart failure hospitalization compared with descriptive model 0 (patients without heart failure according to Framingham criteria). Adjustments for gender, age, glomerular filtration rate, log haemoglobin, log sodium, systolic blood pressure, atrial fibrillation, coronary artery disease, chronic obstructive pulmonary disease, type 2 diabetes mellitus, cancer, and New York Heart Association class. CI, confidence interval; HR, hazard ratio. had several co-morbidities, as expected in patients in their 80s, reflecting frailty. This could contribute to explain why in a previous analysis from KaRen, outcomes were greatly determined by non-CV predictors, in particular age, non-CV syncope, and anaemia, consistent with frailty. 7 Conversely, it was notable in the present study that HF factors such as those in FC-HF were associated with non-CV outcomes, suggesting complex interactions between HF factors and comorbidities in determining CV and non-CV outcomes.
Prognostic implications of the Framingham criteria
At enrolment in the KaRen study, FC-HF was part of the inclusion criteria. However, in this study, we assessed their prevalence and prognostic implication post-discharge at ambulatory follow-up as part of the four different descriptive models. We did not aim to diagnose HFpEF at stable followup. In the clinical setting, the clinician relies on patient history and clinical assessment, regardless of LVEF. At follow-up after an acute HF admission, it would be valuable to know if signs and symptoms such as FC-HF can predict prognosis and cause-specific prognosis or if any single clinical signs carry greater prognostic importance than others. We found that the absence of FC reflected better outcome and in univariate analysis, FC-HF was associated with outcome. Analysing FC one by one, pleural effusion did predict the primary endpoint; however, it is an unspecific sign that can be related to other diagnoses.
Heart failure with preserved ejection fraction descriptive models 2 and 4, both including NP criterion, significantly predicted non-CV death after adjustments possibly reflecting frailty of individuals fulfilling these descriptive models. However, this (CV death/non-CV death) should be interpreted with caution because cause of death was unknown in a large proportion (26%).
Natriuretic peptides and echocardiography are increasingly available (although not always used) both in the acute setting and at follow-up, enabling diagnosis establishment and use of combined measures for prognostic assessment. The echocardiographic HFpEF criteria have evolved to include the combination of high filling pressures with structural changes such as LAVI and LV hypertrophy or mass, and we have previously shown in KaRen that ESC echocardiography criteria were present in 76% of stable HFpEF 13 and E/é in stable HFpEF predicted outcomes.
14 In contrast, in the present study focusing on FC-HF, the E/é criteria for HFpEF were part of descriptive model 3 1 but did not add prognostic information compared with structural changes alone as descriptive model 4 (derived from the PARAGON trial).
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We chose the NP and echo inclusion criteria from the PARAGON study as this study was the first to incorporate structural changes such as LAVI and hypertrophy in the inclusion criteria.
As in PARAGON, we used separate NP elevations for sinus rhythm and atrial fibrillation patients to potentially identify patients with worse outcome. In a registry-based study from Sweden, we have previously showed that NPs were of particular prognostic value in HFpEF. 15 Although NP criteria (descriptive model 2) in the present study added to predicting the primary outcome, the further addition with echocardiographic criteria was superior in identifying patients with poor outcome (Figure 3) . Although our mortality analyses (CV death/non-CV death) should be interpreted with caution due to a large proportion of deaths by unknown cause, we found that the addition of NPs and echocardiographic HFpEF criteria (descriptive models 2 and 4) significantly predicted non-CV death after adjustments, which could reflect frailty.
Implications for future studies of heart failure with preserved ejection fraction
Only a quarter of our patients would have been eligible for PARAGON reflecting the major difference between a registry cohort and an RCT. The PARAGON criteria as well as NP + ESC echocardiography criteria were fulfilled in a quarter of the patients and indeed provided enrichment for predicting the composite outcome. Taken together, this suggests that even in patients with recent acute HF hospitalization, verification of both HF signs and symptoms and reassessment of NPs and echocardiography criteria are helpful to ensure increased risk of HF events. However, these parameters also predicted non-CV events. Thus, design of HFpEF trials remains difficult, because this needs to ensure the presence of HF, sufficient risk of CV events, not too high risk of non-CV events (which presumably are not affected by HF specific interventions), and a stage of the syndrome where intervention may be the most effective.
Limitations
The four different HFpEF descriptive models applied in the present study were created post hoc, and no sample size calculation was made based on their presence or distribution yielding a small sample size. It is therefore possible that our study had a limited power to independently predict prognostic factors. Furthermore, the HFpEF descriptive model reflects the time when the KaRen study was designed, and hence, some of our study patients had HF with midrange ejection fraction according to current definitions. 1 In analysing CV death and non-CV death, there is uncertainty because cause of death was unknown in 26% of patients. Finally, patients who died prior to outpatient visit were excluded and may have been more likely to meet HF criteria, had they made it Prognostic impact of Framingham heart failure criteria in HFpEF to the outpatient follow-up, but even assuming all these patients would have met criteria, still only 30% met HF criteria at follow-up.
Conclusions
In HFpEF patients, HF according to the FC-HF was present in a quarter of patients, whereof 10% were in NYHA class IV. Most met NP and echocardiography criteria for HFpEF. Residual FC-HF at follow-up tended to be associated with increased risk for mortality and HF hospitalization, further strengthened by NPs and echocardiographic criteria, highlighting its role in clinical risk assessment and in identifying patients for future HFpEF research.
